bluebird bio, Inc. (BLUE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.8100 |
| Open | 5.1000 |
| Bid | 2.9600 x 1000 |
| Ask | 2.9600 x 900 |
| Day's Range | 2.6900 - 5.5300 |
| 52 Week Range | 2.5200 - 8.5200 |
| Volume | |
| Avg. Volume | 4,627,162 |
| Market Cap | 312.701M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6300 |
| Earnings Date | Nov 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.29 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BLUE
Related Research
- bluebird bio, Inc.Analyst Report: Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.RatingFair ValueEconomic MoatyesterdayMorningstar
Business WireLong-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
SOMERVILLE, Mass., December 09, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or "bluebird") today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease through five years of follow-up (median 35.5 months, range 0.3-61 months). Data were highlighted in a press briefing at the 65th American Society of Hematology
The Wall Street JournalFDA Approves World’s First Crispr Gene-Editing Drug for Sickle-Cell Disease
The U.S. has approved the world’s first medicine employing Crispr technology, a Nobel Prize-winning discovery that promised a powerful new tool to treat disease.
Business Wirebluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
SOMERVILLE, Mass., December 08, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "bluebird") today announced the details of its U.S. commercial infrastructure to support timely, equitable access to LYFGENIA™ (lovotibeglogene autotemcel, also known as lovo-cel), an FDA-approved gene therapy for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events (VOEs). The LYFGENIA launch builds on bluebird’s demonstrated success deliv
